title: Linezolid: safety and efficacy in special populations.
abstract: Linezolid has been in general use in the UK since 2000. Although toxicity, particularly haematological and neurological, has been an issue, linezolid has proved to be an effective alternative to glycopeptides in the treatment of Gram-positive infections. Since its original licence for the treatment of skin and soft tissue infections and pneumonia, there have been reports of its successful use in the treatment of bone and joint infections, endocarditis, and other difficult-to-treat infections.
authors.affiliation: Department of Microbiology, Newcastle upon Tyne Hospitals Trust, Freeman Hospital, High Heaton, Newcastle upon Tyne, UK. kate.gould@nuth.nhs.uk
authors.forename: F Kate
authors.initials: FK
authors.lastname: Gould
mesh_terms: D000081:Acetamides / Q000008:administration & dosage* / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D000069349:Linezolid; D010003:Osteoarthritis / Q000188:drug therapy; D023303:Oxazolidinones / Q000008:administration & dosage* / Q000009:adverse effects*; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D017192:Skin Diseases, Bacterial / Q000188:drug therapy; D018461:Soft Tissue Infections / Q000188:drug therapy; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid